Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 1/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 6/20 | 0.40 |
| ▸ | EED | O75530 | 1/20 | 0.38 |
| ▸ | CYP46A1 | Q9Y6A2 | 6/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
| ▸ | LPL | P06858 | 1/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14321596 | 0.93 | NOTUM (0.48) | PDK2NOTUMEEDCYP46A1 | |
| SCHEMBL14167596 | 0.86 | PDK2 (0.45) | PDK2NOTUMEEDCYP46A1RORC | |
| SCHEMBL14322213 | 0.83 | NPY5R (0.42) | FFAR4AKT1LPLLIPG | |
| SCHEMBL30814862 | 0.83 | NPY5R (0.42) | FFAR4AKT1LPLLIPG | |
| SCHEMBL13420961 | 0.83 | NOTUM (0.60) | NOTUM | |
| SCHEMBL2190473 | 0.82 | LPL (0.39) | EEDLPLLIPG | |
| SCHEMBL22290809 | 0.82 | LIPG (0.40) | NOTUMFFAR4LPLLIPGROCK1 | |
| SCHEMBL14321795 | 0.81 | SMN1; SMN2 (0.43) | NOTUMACKR3 | |
| SCHEMBL15579191 | 0.81 | LGMN (0.55) | PDK2 | |
| SCHEMBL14321809 | 0.81 | SCN9A (0.38) | PDK2NOTUMLPLLIPGROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2723741-B1 | SUBSTITUTED IMIDAZOPYRIDINYL-AMINOPYRIDINE COMPOUNDS | ARQULE INC (US) | 2016-04-27 | — | — | EP | disclosed |
| US-8962619-B2 | Substituted imidazopyridinyl-aminopyridine compounds | ARQULE, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8962619-B2 | Substituted imidazopyridinyl-aminopyridine compounds | ARQULE, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8962619-B2 | Substituted imidazopyridinyl-aminopyridine compounds | ARQULE, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| EP-2723741-A2 | SUBSTITUTED IMIDAZOPYRIDINYL-AMINOPYRIDINE COMPOUNDS | ArQule, Inc. (US) | 2014-04-30 | — | — | EP | disclosed |
| US-20140073635-A1 | Substituted Imidazopyridinyl-Aminopyridine Compounds | ARQULE, INC. | 2014-03-13 | — | — | US | disclosed |
| US-20140073635-A1 | Substituted Imidazopyridinyl-Aminopyridine Compounds | ARQULE, INC. | 2014-03-13 | — | — | US | disclosed |
| US-20140073635-A1 | Substituted Imidazopyridinyl-Aminopyridine Compounds | ARQULE, INC. | 2014-03-13 | — | — | US | disclosed |
| US-8609688-B2 | Substituted imidazopyridinyl-aminopyridine compounds | ARQULE, INC. (US) | 2013-12-17 | — | — | US | disclosed |
| WO-2012177844-A2 | SUBSTITUTED IMIDAZOPYRIDINYL-AMINOPYRIDINE COMPOUNDS | ARQULE, INC. (US) | 2012-12-27 | — | — | WO | disclosed |
| US-20120329791-A1 | Substituted Imidazopyridinyl-Aminopyridine Compounds | ArQuele, Inc. (US) | 2012-12-27 | — | — | US | disclosed |
| US-20120329791-A1 | Substituted Imidazopyridinyl-Aminopyridine Compounds | ArQuele, Inc. (US) | 2012-12-27 | — | — | US | disclosed |
| US-20120329791-A1 | Substituted Imidazopyridinyl-Aminopyridine Compounds | ArQuele, Inc. (US) | 2012-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329791-A1 | Substituted Imidazopyridinyl-Aminopyridine Compounds | MKI67, CDK4, ABL1 | PDK2 1038/4885NOTUM 3885/4885EED 505/4885 |
| US-20140073635-A1 | Substituted Imidazopyridinyl-Aminopyridine Compounds | MKI67, CDK4, ABL1 | PDK2 1038/4885NOTUM 3885/4885EED 505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.